Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

aap: Market launch of polyaxial LOQTEQ® VA ankle system

aap Implantate AG
Posted on: 20 Oct 16
  • Polyaxial system enables flexible treatment of ankle fractures

aap Implantate AG (" aap" ) announces the market launch of the polyaxial LOQTEQ® VA Distal Tibia and Fibula Plates 2.7/3.5. The system enables the flexible treatment of ankle fractures, thereby addressing one of the most frequent fractures of load-bearing joints. The LOQTEQ® VA Distal Tibia and Fibula Plates 2.7/3.5 belong to the LOQTEQ® VA (VA = Variable Angle) product family, which are polyaxial implants that facilitate inserting angle-stable screws at different angles. Polyaxial implants are required for treating areas such as the ankle that in surgery require both angle stability and flexibility in the insertion of screws.

Ankle fractures are among the most frequent fractures that receive trauma surgery treatment. To meet patients' growing demands, a fast, mobilization-stable treatment with a permanent retention of the repositioning result is required. The special combination of anatomically preformed and angle-stable plates in conjunction with freely selectable screw angles and user-friendly instruments fulfils all the requirements of modern fracture management.   The LOQTEQ® VA ankle system 2.7/3.5 consists of distal plates for the treatment of medial and anterolateral fractures of the tibia and plates for treating lateral fractures of the fibula. Variable, angle-stable round holes in the part of the plate that is close to the joint have been added to the monoaxial version of the LOQTEQ® ankle system that is already successful on the market and the profile of the tibia plates has been further optimised. The LOQTEQ® Fibula Plate 3.5 was additionally converted for 2.7 mm diameter screws in the distal part in order to fix small fracture fragments and minimise protrusion of screw heads in the event of deviations from the pre-set angle. The anatomical fit of the system as well as the low profile, the rounded edges and the smooth surfaces reduce the risk of soft tissue irritation.   aap will shortly be launching further polyaxial variants of different LOQTEQ® products for various anatomical areas in the market.

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@ aap .de  

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via GlobeNewswire
HUG#2050278
GlobeNewswire
globenewswire.com

Last updated on: 21/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.